thor util novel base pair technolog develop modifi cytokin
treat variou oncolog autoimmun indic lead asset
modifi optim engag
receptor avoid toxic aldesleukin maintain anti-tumor
respons compani also develop modifi version
oncolog indic offer upsid initi buy pt
jefferi joint book-run manag thor initi public offer dec
show improv preclin safeti profil vs effect rcc
melanoma major drawback high dose aldesleukin therapi seriou ae
profil includ vascular leak syndrom vl pegyl specif
locat minim treg activ maintain cell nk cell respons
dose anim studi shown improv therapeut window w/ compar
compani plan administ higher dose human compar
efficaci monotherapi studi could signal posit readthrough synthorx
intend conduct phase dose escal studi all-com well
combin checkpoint inhibitor sensit tumor competitor
agent shown clinic respons monotherapi
drive debat around actual contribut efficaci combin set
demonstr object respons monotherapi would serv
catalyst stock provid proof-of-concept regard thor platform confid
achiev enhanc respons combin therapi expect initi
interim data biomark ye add efficaci respons data may
serv catalyst thor share given lack clinic data signific risk
discount model howev clinic data could offer sig upsid
see add upsid interim efficaci data downsid lack
efficaci
earli pipelin offer addit upsid synthorx also develop three addit
asset synthorin pegyl manner distinct would distinctli
promot treg respons address autoimmun disord synthorin
develop enhanc pk properti cytokin improv clinic
respons elicit cell nk cell respons w/out risk vl
co select ind candid molecul
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
assum risk-adjust nsclc melanoma
base preclin data believ could
differenti properti compar therapi
expect could deliv larger dose compar
therapi without incur relat advers
believ fast follow clinic
develop strategi
current employ signific risk adjust base
earli stage
derisk posit clinic data
nsclc lower risk adjust everi
rcc lower risk adjust everi would
ind file solid tumor
ph i/ii singl agent biomark poc data solid tumor
monotherapi
initi ph i/ii combo trial sensit solid tumor
biomark poc data sensit solid tumor
melanoma lower risk adjust everi
price target dcf-base lower
risk adjust across indic
autoimmun synthorin
derisk posit clinic data upsid model
select ind candid synthorin
select ind candid synthorin
select ind candid autoimmun disord
ind file autoimmun disord
all-clin regulatori commerci failur price
page
pleas see import disclosur inform page report
synthorx biotechnolog compani focus develop modifi
biolog call synthorin address oncolog autoimmun indic
compani novel base pair technolog allow highli precis site-
specif incorpor moieti enhanc pharmacokinet
pharmacodynam properti cytokin biolog compani
lead asset pegyl alpha form design
avoid toxic side effect seen clinic approv form
aldesleukin specif integr singl coval attach
demonstr improv half-lif hour mice
signific increas cell nk cell increas
regulatori cell non-human primat model addit evid
vascular leak syndrom observ dose elicit maximum
pharmacodynam respons compani begin phase dose-
escal studi assess effect monotherapi
combin checkpoint inhibitor addit compani
current develop pegyl form use autoimmun
indic well modifi cytokin use oncolog
indic feel platform technolog offer potenti address
may current limit pegyl chemistri
offer optim pk/pd profil tackl mani issu seen
competitor agent develop initi buy
optim engag receptor lead improv pd respons
safeti profil key challeng develop next gener agent
strike balanc mitig treg activ respons promot
vascular leak also elicit activ expans cytotox cell
nk cell achiev minim engag alpha chain
receptor maxim engag beta chain
minim alpha receptor engag higher degre competitor
maintain beta chain engag compar nativ
improv receptor engag lead enhanc extend
signal cell critic maintain effector function well
improv persist cell mous tumor model importantli
enhanc cytotox attribut come expens elev treg
eosinophil dose test non-human primat improv therapeut
window could potenti translat improv clinic respons
respons rate monotherapi studi could signal posit readthrough
combin studi synthorx intend conduct phase dose escal
studi all-com well combin checkpoint
inhibitor sensit tumor unlik nativ competitor agent
shown clinic respons monotherapi drive
debat around actual contribut efficaci combin set
case demonstr object respons monotherapi
would provid proof-of-concept regard design modifi
cytokin greater confid achiev enhanc cytotox respons
combin checkpoint therapi
page
pleas see import disclosur inform page report
autoimmun diseas synthorin i/o
offer addit upsid compani also current develop addit
synthorin first synthorin pegyl manner distinct
instead promot treg respons treg signal
pathway implic variou autoimmun diseas low dose
therapi shown efficaci cgvhd addit
shown elicit effector cell nk cell respons mous tumor
model without associ risk vascular leak syndrom pegyl il-
synthorin develop enhanc pk properti cytokin
synthorx biopharmaceut compani focus develop modifi biolog
treat cancer autoimmun disord compani util proprietari novel
base pair technolog gener drug enhanc properti distinct
engin mean compani lead asset pegyl use
page
pleas see import disclosur inform page report
clinic failur compani
biotechnolog pharmaceut
develop treatment futur clinic failur lead delay approv
possibl discontinu program
regulatori failur fda could determin compani nda inadequ
could delay approv delay approv timelin could impact earn
commerci failur estim may reli success compani receiv
drug reimburs private/publ medic insur payor
financ risk thor may need rais addit fund support sg
 activ time model equiti financ occur
model partnership agreement may reduce/elimin need
page
pleas see import disclosur inform page report
improv upon given current
clinic stage comparison preclin dataset made
compar appear demonstr
improv pharmacodynam respons overal exhibit enhanc extend
durat phosphoryl signal cell mice well
exhibit durabl elev intratumor cell mous model
melanoma compar perhap importantli optim
alpha profil molecul exhibit lower
treg cell vs nativ non-human primat increas treg
level dose rang test maxim lymphocyt expans observ
maximum toler dose non-human primat studi maxim
lymphocyt expans observ maximum toler dose see exhibit
comparison
commerci scale-up feasibl biolog manufactur
synthesi uniqu compar approach biolog given
use use unnatur nucleotid non-natur amino acid requir
specif compon enabl bacterium-bas transcript translat
cytokin see pg background synthorx platform technolog result
addit complex ad tradit process plasmid-bas express
host cell base synthesi biolog synthorx manag demonstr
progress scale-up progress
manufactur compani track liter ferment run
compani also enter agreement cytov biolog
develop scale-up product support in-vivo studi believ
compani demonstr progress meet expans scale-up object
track continu progress head human studi
integr non-natur amino acid creat anti-drug-
antibodi design compani analyz sequenc
amino acid residu act anchor mhc class ii present peptid
bind prefer exist among differ mhc allel site incorpor
predict lead mhc class ii present
cell base assay demonstr mhc present
donor mhc allotyp suggest site incorpor novel
nucleotid amino acid prefer mhc present addit
moieti coval link novel amino acid inhibit present
epitop mhc receptor overal design appear strongli
mitig product anti-drug antibodi possibl rule
complet individu shown present
certain mhc allotyp aforement cell present assay
drive respons checkpoint refractori patient
esmo roch present data fusion antibodi
mutat bind alpha chain receptor notabl drug
show pr melanoma patient progress checkpoint therapi despit
small sampl size first instanc engin not-alpha
page
pleas see import disclosur inform page report
version shown single-ag efficaci patient progress
checkpoint therapi stand contrast nektar show object
respons checkpoint refractori patient monotherapi
result provid support not-alpha design
synthorx platform technolog come work dr floyd romesberg
scripp research institut public research team demonstr
abil util unnatur base pair ubp transcript translat
bacteri plasmid rational expand genet alphabet outsid well-
known nucleotid expand capabl synthet biolog
enhanc protein function consequ biolog capabl organ
initi studi malyshev et al natur author demonstr two
unnatur base pair dnam success integr plasmid
effici replic coli strain provid nucleotid triphosph
transport allow entri ubp cytoplasm molecular structur
ubp schemat ubp integr determin ubp retent
replic coli shown exhibit second public zhang et al natur
romesberg group built upon initi studi demonstr ubp
util make unnatur codon ex axc gyc etc
transcrib subsequ decod trna unnatur anticodon promot
effici translat demonstr in-vitro assay show incorpor
serin residu posit superfold green fluoresc protein use
page
pleas see import disclosur inform page report
exhibit unnatur base pair success replic ubp contain plasmid dna coli
chemic structur ubp
 schemat incorpor ubp plasmid dna
 demonstr success replic ubp-contain plasmid use biotin-streptavidin gel-shift assay
novel nucleotid amino acid allow site-specif modif
abil insert unnatur anticodon at-wil within protein-cod plasmid open
distinct possibl commerci protein engin yet
unfeas specif unnatur codon/anti-codon trna approach allow
site-specif insert novel amino acid uniqu side chain enabl effici
bioconjug pharmacolog enhanc current bio-conjug
approach pegyl reli chemistri link lysin n-terminu
protein method lead heterogen product mixtur due uncontrol
attach lysin residu limit control pk properti synthorx
platform facilit singl site-specif conjug cytokin protein
choic chemistri facilit bio-conjug novel amino acid
contain azid side chain allow dbco-peg base click-chemistri
manufactur transcript translat novel amino acid
synthorx in-licens technolog scripp research institut develop
portfolio cytokin asset use synthorx asset exampl
protein synthesi approach begin dna express vector encod
cytokin ad unnatur codon select site trna correspond
unnatur anticodon transport capabl shuttl unnatur nucleotid
cytoplasm host bacteri strain orthogon trna synthetas capabl
charg unnatur trna novel amino acid vector express within
proprietari coli strain capabl undergo necessari replic transcript
translat need synthes novel protein last compon
presenc novel amino acid case amino acid
azid side chain element place host bacteri strain
page
pleas see import disclosur inform page report
synthes modifi cytokin azid contain amino acid purif
click-chemistri conjug step yield final pegyl protein exhibit
one question aris scalabl protein synthesi approach commerci
level compani demonstr advanc matter progress
liter shake flask manufactur run liter fermenter-bas
manufactur compani track liter ferment run
compani also enter agreement cytov biolog develop
scale-up product support in-vivo studi
previous mention synthorx
licens expand genet alphabet
technolog romesberg lab/ scripp research institut compani
robust patent portfolio around multipl aspect platform includ proprietari
host coli strain x/i synthet nucleotid artifici base transport unnatur
nucleic acid synthesi trna unnatur x/i nucleobas well singl
exhibit synthesi novel protein use expand genet alphabet novel amino acid
page
pleas see import disclosur inform page report
clinic efficaci poor pharmacolog power immuno-
cytokin play role activ expans effector cell well nk
cell cell base upon abil activ cell nk cell popul
one first cytokin test clinic eventu approv
trade name proleukin aldesleukin treatment metastat rcc
melanoma approv high dose therapi base upon impress respons rate
time orr mdor month metastat rcc patient
howev respons rate counter sever side effect seen patient
therapi hypotens vascular leak syndrom coma well-not
side effect profil treatment attribut high dose need
counteract short half-lif serum roughli minut skrombola
freling expert clin immunol poor pharmacolog high-dos
therapi specif attribut sub-optim respons receptor
receptor compos alpha beta gamma subunit bind
function along promot eosinophil degranul vasculatur lead
vascular leak syndrom hand bind activ receptor
beta/gamma receptor promot cytotox cell nk cell respons
well-establish role known play enhanc anti-canc immun
respons mani research group set optim pharmacolog
enhanc therapeut window
optim interact receptor synthorx develop thor-
novel engin agent singl stabl coval attach
synthet amino acid incorpor protein structur target
pegyl specif site block interact alpha chain
receptor maintain interact beta/gamma complex result
alpha cytokin result abl preferenti promot effector cell
nk cell respons suppress regulatori cell addit
improv pharmacolog provid potenti improv therapeut
index treatment allow frequent dose reduct sever side
pegyl minim immunogen select site incorpor
novel azide-contain amino acid chosen partial base upon cell-screen
approach identifi locat would optim block effect conjug
alpha subunit receptor potenti concern howev
gener anti-drug-antibodi modifi cytokin contain element
unnatur amino acid address compani perform in-silico analysi
sequenc predict amino acid residu would act anchor mhc class
ii present site select conjug predict
anchor residu mhc-ii present valid via cell-bas peptid
page
pleas see import disclosur inform page report
present assay use human donor cell allotyp repres donor
cell allotyp result mhc present peptid
demonstr select bind beta chain preferenti
activ cytotox cell determin whether select engag
beta chain receptor surfac plasmon reson assay perform use
concentr gradient um cytokin seen exhibit
demonstr preferenti bind beta chain minim bind
alpha chain receptor stand contrast wildtyp
demonstr engag alpha beta chain pegyl
also appear minim impact engag beta chain show
approxim differ beta chain engag vs nativ
concentr function demonstr alpha profil
shown via phosphoryl signal ex-vivo regulatori cell
effector cell exhibit show decreas potenc cell
activ vs wherea show similar cell activ confirm
alpha action
exhibit bind affin receptor alpha beta chain
page
pleas see import disclosur inform page report
exhibit ex-vivo activ treg effector cell
exhibit enhanc half-lif increas level relev
immun cell type compar aldesleukin demonstr half-lif
hour vs hour mice improv half-lif translat improv
pharmacodynam effect in-vivo mous model show sustain
maxim level express cell hour singl dose
compar favor dose mg/kg exhibit acut
respons peak within first half hour declin thereaft although
compar aldesleukin also show increas level peripher nk cell
memori cell compar vehicl contrast exhibit minim increas
peripher reg cell cours day exhibit
exhibit ex-vivo activ treg effector cell mice
page
pleas see import disclosur inform page report
demonstr tumor penetr retent enhanc
cell infiltr use mous melanoma model dose mg/kg
compani demonstr exhibit tumor half-lif plasma half-lif
vs hr retent tumor mass lead signific increas
cell percentag tumor infiltr lymphocyt tumor day
time percentag treg cell found increas
period dose exhibit also exhibit dose-depend single-ag
effect colon tumor model signific decreas tumor volum
observ dose mg/kg
show addit effect treatment colon tumor mous
model given treatment enhanc cytotox immun cell respons
combin checkpoint inhibitor therapi provid potenti synergist
effect hypothesi test colon tumor mous model mice
treat anti-
combin seen exhibit combin provid
reduct tumor volum compar control demonstr addit
effect compar anti monotherapi
exhibit tumor pharmacokinet cytotox action monotherapi combo
top biodistribut tumor retent bottom left percent cell infiltr melanoma tumor bottom right percent decreas tumor volum
combin therapi
non-human primat data show effect lymphocyt expans
promis safeti profil synthorx conduct pre-clin studi cynomologu
monkey assess pharmacodynam effect well toler weekli dose
concentr mg/kg show sustain elev level
peripher cell level also increas cell exceed
posit stain mg/kg dose level importantli dose level
show evid eosinophilia vascular leak syndrom exhibit
compani recent perform dose evid vascular leak
syndrom observ form elev eosinophil level nonetheless data
page
pleas see import disclosur inform page report
exhibit pharmacodynam non-human primat
suggest possibl enhanc dose aldesleukin treatment show sign
eosinophilia ug/kg lethal ug/kg
employ primarili pegyl approach improv therapi
nektar therapeut buy steinberg current hold lead advanc
modifi therapi piii trial melanoma rcc asset
prodrug form drug form via bind chain
slowli releas overtim yield increasingli activ protein chain
bound region contact alpha subunit receptor therebi
reduc affin alpha/beta/gamma receptor greater extent
beta/gamma receptor chain releas increasingli bioactiv form
reveal version biolog activ
show enhanc reduct bind alpha receptor
comparison surfac plasmon reson plot vs reveal
form exhibit residu bind alpha chain
receptor wherea show essenti zero engag alpha
receptor addit also show reduc engag beta/gamma
receptor well form show reduc bind greater
exhibit pharmacokinet also exhibit greater serum half-lif
hour iv dose mg/kg mous vs hour speci lower
hour half-lif activ speci compris
nake
show delay attenu effector signal vs thor-
phosphoryl signal shown critic signal pathway
maintain cell well nk cell function in-vivo result serv
valid measur degre effector cell function dose mice mg/kg
show level cell around approxim hour
initi dose level decreas around hour compar
favor show cell hour
dose mg/kg point level began decreas exhibit
page
pleas see import disclosur inform page report
enhanc pharmacodynam effect like attribut increas half-lif
greater degre beta chain engag compar
exhibit comparison alpha receptor bind
left plot right plot
exhibit demonstr greater cell effector signal vs mice
show enhanc persist cell mous model
melanoma mous model melanoma singl iv dose mg/kg show
elev intratumor level cell cell day
dose exhibit compar favor iv dose
mg/kg melanoma model saw cell level remain elev
day point cell level drop significantli though
compar aldesleukin overal data suggest promot durabl
tumor infiltr cell compar particular mous model
page
pleas see import disclosur inform page report
exhibit comparison intratumor cell level mous model melanoma
show extend durat lymphocyt expans vs
non-human primat singl dose cynomolog monkey
ug/kg use iv subcutan deliveri mean demonstr increas
lymphocyt level within hour dose peak lymphocyt level
last hour decreas thereaft maxim pd effect seen
ug/kg differ substanti ug/kg dose singl dose
mg/kg maximum toler dose exhibit increas lymphocyt level
hour peak lymphocyt level last hour
point level come acut exhibit overal demonstr robust
effect expand lymphocyt level primat well maximum toler
dose appear modestli improv durat max pharmacodynam
exhibit comparison lymphocyt expans non-human primat
page
pleas see import disclosur inform page report
demonstr earli signal vl nektar present phase
patient advanc solid tumor treat monotherapi
establish safeti toler maximum toler dose dose rang test
studi mg/kg
mg/kg dose well data demonstr expand lymphocyt human
dose mg/kg mg/kg increas prolifer cell
peripher blood tumor howev grade advers event note
studi includ instanc hypotens dose
dose revers iv fluid interpret posit context
suggest limit dose consequ may fail elicit
demonstr impress earli efficaci advanc solid
tumor combin checkpoint inhibitor dose escal
safeti data set phase trial evalu combin
nivolumab advanc solid tumor phase dose escal portion studi
evalu i/o treatment nave patient melanoma known braf statu
rcc nsclc dose mg/kg mg/kg
schedul togeth nivolumab dose mg establish
mg/kg nivo mg advanc studi
phase dose expans portion would target differ tumor type i/o
nave pt i/o relaps refractori patient
data show orr advanc melanoma pt
i/o nave note patient neg
treatment i/o nave rcc patient show orr cr
data nsclc patient also present patient prior system
therapi prior therapi best orr patient orr
patient combin respond
unconfirm take respons rate impress unclear moment
due small number patient await data continu
enrol expans cohort phase portion gain clariti around
effect size provid nivo therapi effect line improv upon
exhibit respons rate nivo nivo ipilimumab studi
high potenc toward
intermedi affin receptor medicenna therapeut current develop
engin fusion protein compris mutat
increas affin intermedi receptor low-effector fc domain
page
pleas see import disclosur inform page report
enhanc pk properti domain deriv use combin direct
evolut comput structur model approach preclin data present
compani demonstr show roughli
fold higher potenc intermedi affin receptor pm measur
signal cell vs howev unlik potenc also
increas high affin receptor measur treg
activ exhibit increas potenc treg cell could
potenti lead undesir activ treg function mediat eosinophilia
subsequ vl make dose difficult data anim model especi
non-human primat requir better assess pk/pd benefit profil
exhibit treg cell activ use
escal hold current develop novel fusion
protein design target intermediate-affin receptor pi/ii clinic
develop protein fusion extracellular domain high affin
receptor circularli permut therebi steric hinder engag
intermedi affin receptor complex protein show similar potenc toward
intermedi affin receptor measur t-lymphocyt cell line show
significantli reduc potenc high-affin complex measur nk cell line
exhibit engag intermedi affin receptor mirror
show reduc serum half-lif hour mice iv dose vs
hour iv dose mg/kg shorter rel half-lif
appar earli pk data first human dose escal data present
singl dose ug/kg administ patient show
approxim window serum concentr exceed
cell nk cell activ result need administ
daili minut infus consecut day day cycl dose
schedul demonstr dose-depend increas cell max
cells/ul nk cell max cells/ul grade advers event note
sign vascular leak syndrom dose escal portion studi current
on-go expans dose ug/kg test next
page
pleas see import disclosur inform page report
exhibit potenc intermedi high affin receptor
alpha fap express tumor roch
current develop engin cytokin consist mutat
domain fuse fap fibroblast activ protein target monoclon antibodi
mutat domain retain affin beta-gamma complex
abolish affin alpha subunit receptor fap membran proteas
whose express varieti tumor associ poor prognosi high
tumor associ
thought contribut tumor
aggress roch recent present singl agent phase dose escal data
protein esmo studi enrol patient metastat solid
tumor dose escal portion administ iv
patient treatment refractori melanoma scc enrol extens
cohort confirm safeti pk/pd patient enrol studi
orr post checkpoint inhibitor melanoma patient saw pr melanoma pt
orr furthermor observ sign vl peripher edema weight gain
rash observ hypotens grade note
mg/kg dose lead single-ag efficaci await
matur data gain clariti around efficaci agent feel first
exampl not-alpha agent demonstr earli efficaci improv
advers event profil aldesleukin
demonstr efficaci monotherapi
confid go dose expans combin therapi studi
point take consider evalu compet program
whether agent abl drive clinic respons
monotherapi set recal aldesleukin approv base upon orr
cr pr metastat rcc orr cr pr metastat
melanoma monotherapi contrast demonstr complet partial
respons monotherapi studi patient advanc metastat
melanoma bladder rcc chondrosarcoma leiomyosarcoma patient studi
split dose cohort across dose rang mg/kg
page
pleas see import disclosur inform page report
